Listeria News and Research

RSS

Listeria is a bacterial genus containing seven species. Named after the English pioneer of sterile surgery, Joseph Lister, Listeria species are Gram-positive bacilli and are typified by ''L. monocytogenes'', the causative agent of listeriosis.

USPTO issues patent for Advaxis’ live Listeria HER2/neu immunotherapy

The U.S. Patent and Trademark Office has issued to Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, patent number 7,784,729 titled "Methods and Compositions for Immunotherapy of Cancer," based upon patent application 10/949,667.

10 Sep 2010

Advaxis receives USPTO patent for Listeria vaccine

The U.S. Patent and Trademark Office has approved Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu (human epidermal growth factor receptor 2), when using the company's proprietary listeriolysin O (LLO) fusion platform technology.

9 Sep 2010

Unpredictable food poisoning

While we are often exposed to bacteria in our food which could cause food poisoning, we don't always become ill - why should this be so?

6 Sep 2010

Advaxis' 'Prokaryotic peptides for enhancing antigen immunogenicity' European patent application allowed

Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has been notified by the European Patent Office that patent application WO2001/072329, for the use of Prokaryotic PEST-Like Peptides for Enhancing Immunogenicity of Antigen has been allowed for issuance. This patent will be #1,303,299 when granted, and will be licensed exclusively to Advaxis by the University of Pennsylvania.

26 Aug 2010

USPTO to allow patent for Advaxis’s new vaccine technology

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has been notified that the US Patent and Trademark Office (USPTO) will allow a patent issuance of its application No. 11/785,249 entitled "Antibiotic Resistance Free Vaccines and Methods for Constructing and Using Same."

21 Aug 2010

Advaxis completes low dose group patient dosing in phase II cervical dysplasia clinical trial study

Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has completed the nine (9) doses to be administered to the three (3) vanguard patients in the low dose group of its phase II cervical dysplasia clinical trial study.

19 Aug 2010

Advaxis, Vibalogics to develop storage-stable formulation for live Listeria vaccines

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company and Vibalogics GmbH, a German biologics manufacturing company, have agreed to co-develop a room temperature stable, processing technology for live vaccines originally engineered for Advaxis.

12 Aug 2010

Advaxis receives India’s DCGI approval for ADXS11-001 Phase II clinical trial for cervical cancer

Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has received formal permission from the Drugs Controller General India (DCGI) to conduct a Phase II clinical trial of ADXS11-001, the Company's flagship drug construct, among 110 women with advanced, metastatic cervical cancer that has progressed subsequent to treatment with cytotoxic therapy. 55 women will receive ADXS11-001 alone, 55 will receive a combined regimen of both ADXS11-001 and cytotoxic therapy.

4 Aug 2010

Health and Safety Watch launches new website to help Canadians access health-related information

Health and Safety Watch Inc., an organization established to help Canadians manage all types of health and safety hazards, today officially launched www.HealthandSafetyWatch.com, a new website designed to give Canadians easy access to real-time information about the 500-plus product, food, and drug recalls, as well as health advisories, that occur every year.

3 Aug 2010

U.S. Department of Justice seeks permanent injunction against N.Y. food processor over listeria contamination

The U.S. Department of Justice, in an action initiated by the U.S. Food and Drug Administration, is seeking a permanent injunction against NY Gourmet Salads, Inc., a processor of ready-to-eat deli salads, seafood salads, and cream cheeses in Brooklyn, N.Y., and Leonard F. Spada, the company's president.

3 Aug 2010

Life Technologies launches new assay to detect deadly strain of E. coli

Life Technologies, a provider of innovative life science solutions, announced at the International Association of Food Protection annual meeting the launch of the MicroSEQ E. coli O157:H7 assay, designed to detect the deadly strain of Escherichia coli (E. coli), using the company's industry-leading real-time PCR technology.

2 Aug 2010

Stop & Shop Supermarket announces voluntary recall of Nature's Promise Alfalfa, Zesty Sprouts

The Stop & Shop Supermarket Company has announced a voluntary recall of Nature's Promise Alfalfa and Zesty Sprouts because they have the potential to be contaminated with listeria monocytogenes.

31 Jul 2010

Advaxis provides update on survival information from ADXS11-001 phase 1 trial in cervix cancer

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy.

29 Jul 2010

Advaxis signs definitive purchase agreement with Optimus

Advaxis, Inc., the live, attenuated Listeria monocytogenes immunotherapy company, announced today that it has entered into a definitive purchase agreement with Optimus Capital Partners, LLC d/b/a Optimus Life Sciences Capital Partners, LLC.

20 Jul 2010

Study on how cellular defence systems keep themselves in check from damaging cells themselves

When cells are attacked by bacteria they use all means at their disposal to defend themselves. But cellular defence systems can damage the cells themselves and so need to be kept tightly in check. Recent results help us to understand how this is done and give pointers to new ways of combating disease. Matthias Farlik in the group of Thomas Decker at the Centre for Molecular Biology of the University of Vienna (Max F. Perutz Laboratories) and Mathias Müller of the University of Veterinary Medicine, Vienna have published these findings in the current issue of the journal "Immunity".

16 Jul 2010

Aduro BioTech announces issuance of two important patents

Aduro BioTech, a clinical-stage immunotherapy company, announced today the issuance of two important patents, the formation of a distinguished scientific advisory board, the addition of key members to its Board of Directors, and the reporting of preliminary top line long-term survival data from a Phase 1 clinical trial with 2 year follow-up.

15 Jul 2010

Advaxis completes enrollment of vanguard patient group in phase II clinical trial for cervical intraepithelial neoplasia

Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia.

24 Jun 2010

BGS develops new bio filters for testing E. coli, salmonella, listeria and pseudomonas in food samples

BioSpec Global Solutions Inc., and partner -ICBS Ltd., announced today that it has begun development of three new bio filter for the testing of E. coli, salmonella, listeria and pseudomonas in food samples. Development of the Antibody/antigen multiple discrete filters and optical system for the simultaneous analysis of E.coli, salmonella, listeria and pseudomonas in food samples.

7 Jun 2010

Advaxis doses first patient in FDA-approved phase II CIN trial

Advaxis, Inc., the live, attenuated Listeria monocytogenes biotechnology company, has dosed the first patient in its US Food and Drug Administration -approved, phase II clinical trial in cervical intraepithelial neoplasia, commonly known as cervical dysplasia.

28 May 2010

Small molecule ramps up interferon production in host cells, launching potent immune response

Many disease-causing microbes carry pumps that expel antibiotics, making the bugs hard to kill with standard drugs. Ironically, these same pumps could be the bugs' Achilles heel.